- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT00625404
FEM-PrEP (Truvada®): Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
Phase 3, Multi-center, Double-blind, Randomized, Placebo-controlled Effectiveness and Safety Study to Assess the Role of Truvada® in Preventing HIV Acquisition in Women
This Phase III, double-blind, randomized, placebo-controlled trial enrolled HIV-negative women from 4 sites in 3 countries (Kenya, Tanzania, South Africa). The study's purpose was to investigate the safety and effectiveness of a once-daily Truvada® pill (compared with placebo) in preventing HIV among HIV-uninfected women at risk of becoming infected through sexual intercourse.
The study population included HIV-antibody-negative women between the ages of 18-35 who were at risk of HIV acquisition through sexual intercourse. Each participant was randomized to take either a daily single oral tablet of Truvada®, which is a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg), or an identical placebo.
After enrollment, each participant was followed every four weeks. All participants were followed for an additional eight weeks after study drug was stopped. Incidence rates of HIV infection were compared between the two groups (active drug and placebo) using the intent-to-treat principle.
Обзор исследования
Подробное описание
This Phase III, double-blind, randomized, placebo-controlled trial enrolled HIV-negative women from 4 sites in 3 countries (Kenya, Tanzania, South Africa). The study's purpose was to investigate the safety and effectiveness of a once-daily Truvada® pill (compared with placebo) in preventing HIV among HIV-uninfected women at risk of becoming infected through sexual intercourse.
The study population included HIV-antibody-negative women between the ages of 18-35 who were at risk of HIV acquisition through sexual intercourse. Each participant was randomized to take either a daily single oral tablet of Truvada®, which is a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg), or an identical placebo. All participants received risk reduction counseling and condoms. Women had to be using a study-approved effective non-barrier contraceptive method at the time of enrollment and were asked to do so for the whole period they were on study drug. They received contraceptive counseling throughout the study. Any diagnosed, treatable sexually transmitted infection was treated free of charge.
After enrollment, each participant was followed every four weeks. All participants were followed for an additional eight weeks after study drug was stopped. Participants at risk for Hepatitis B Virus (HBV) flare were followed every four weeks for 12 weeks after stopping study product. Participants who acquired HIV infection during the study stopped taking the study drug at the time of HIV diagnosis, and will be followed for 52 weeks post diagnosis and were referred for care and treatment. Participants who became pregnant stopped taking the study drug but continued follow-up visits. Incidence rates of HIV infection were compared between the two groups (active drug and placebo) using the intent-to-treat principle.
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 3
Контакты и местонахождение
Места учебы
-
-
Nyanza
-
Bondo, Nyanza, Кения
- Bondo Clinic, Bondo District Hospital
-
-
-
-
-
Arusha, Танзания
- Arusha Clinic, Levolosi Health Center
-
-
-
-
-
Bloemfontein, Южная Африка
- Josha Research Center
-
-
Gauteng
-
Pretoria, Gauteng, Южная Африка
- Setshaba Research Centre
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Willing and able (see criterion 2) to provide written informed consent to be screened for and to participate in the trial
- Able to answer a percentage of informed consent screening (75%) and enrollment (100%) comprehension quiz questions correctly
- Between 18-35 years old, inclusive
- At higher risk of becoming HIV infected
- Have a final negative result according to the site-specific screening HIV testing algorithm and a final negative result at enrollment according to the study HIV testing algorithm
Willing to participate in all aspects of the study and to comply with study procedures, for up to 60 weeks, including:
- Be randomized
- Use study product as directed
- Adhere to follow-up schedule and willing to be contacted by site staff between study visits (by phone and/or in person)
- Use a study-approved effective non-barrier method of contraception for the duration of the study
- Take study product, as evidenced by swallowing a vitamin tablet that is similar in size to the study product at enrollment
- Provide contact information and agrees to some form of contact method throughout the study
- Not intending to relocate out of the area for the duration of the study participation and does not have a job or other obligations that may require long absences from the area ( > 1 month at a time)
- In general good health and have no condition (social or medical) which, in the opinion of the Site Investigator, would make study participation unsafe or complicate data interpretation
- Not pregnant or breastfeeding, and does not anticipate a desire for pregnancy during the 52 weeks of on-product participation
Medically eligible at screening including:
- Adequate renal function (serum creatinine ≤ upper limit of normal (ULN) of local range and creatinine clearance ≥ 60ml/min estimated by the Cockcroft-Gault Creatinine Clearance Formula
- Adequate hepatic function (hepatic transaminases ALT and AST < 2x ULN [according to local normal ranges])
- HBsAg negative
- Serum phosphorus levels above the lower limit of the local normal range (according to local normal ranges - grade 3 & 4 hypophosphatemia will be excluded even if within normal local ranges)
- Not received or receiving an experimental HIV vaccine, participating in another HIV prevention study or participating in any other clinical trial with a biomedical intervention
- No clinical signs of liver disease (e.g., ascites, spider angiomata, hepatomegaly, jaundice)
- No definite evidence of glycosuria or proteinuria (i.e., no repeated positive [ ≥ + 1 ] urine dipstick). If a urine dipstick is positive for either glucose and/or protein at the first test, a second urine sample will be tested.
- No history of pathological bone fractures
- No history of adverse reaction to latex
- Not taking any of the following medications: nephrotoxic agents; aminoglycoside antibiotics (including gentamicin); intravenous (IV) amphotericin B; cidofovir; cisplatin; foscarnet; IV pentamidine; oral or IV vancomycin; oral or IV gancyclovir; other agents with significant nephrotoxic potential; drugs that slow renal excretion; probenecid; immune system modulators; systemic chemotherapeutic agents (i.e. cancer treatment medications); systemic corticosteroids; interleukin-2 (IL-2); immunomodulators; interferon (alpha, beta, or gamma); other antiretrovirals (including nucleoside analogs, non-nucleoside reverse transcriptase inhibitors, protease inhibitors or investigational antiretroviral agents)
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Профилактика
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
---|---|
Экспериментальный: Truvada Arm
Daily single oral tablet of Truvada (TDF/FTC), a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
|
Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
Другие имена:
|
Плацебо Компаратор: Placebo Arm
Daily single oral tablet of Placebo.
Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
|
Daily single oral tablet of Placebo.
Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
HIV Infection
Временное ограничение: Cumulative HIV infection between enrollment and 52 weeks
|
HIV Seroconversion, with time to infection refined based on PCR results obtained from stored specimens.
|
Cumulative HIV infection between enrollment and 52 weeks
|
Confirmed Grade 2 or Higher Serum Creatinine Toxicity
Временное ограничение: cumulative toxicity through 52 weeks of product use and 4 weeks post product
|
Repeat specimens were collected to confirm chemistry toxicities.
Grade 2 or higher serum creatinine toxicity was defined as ≥1.4 times the upper limit of normal
|
cumulative toxicity through 52 weeks of product use and 4 weeks post product
|
Frequency of Adverse Events (AEs) During and Within 4 Weeks After Study Product Administration
Временное ограничение: 10-26 months per site
|
The total number of adverse events in the placebo and Truvada arms during and within 4 weeks after study product administration.
|
10-26 months per site
|
Confirmed Grade 3 or Higher Reduction in Phosphorus
Временное ограничение: Through 52 weeks on product and 4 weeks post-product
|
Repeat specimens were collected to confirm chemistry toxicities.
Grade 3 phosphorus reduction was defined as ≤2.4mg/dL
|
Through 52 weeks on product and 4 weeks post-product
|
Confirmed Grade 3 or Higher ALT Elevation
Временное ограничение: Through 52 weeks on product and 4 weeks post-product
|
Grade 3 or higher ALT elevation was defined as ≥ 2.6 times the upper limit of normal
|
Through 52 weeks on product and 4 weeks post-product
|
Confirmed Grade 3 or Higher AST Elevation
Временное ограничение: Through 52 weeks on product and 4 weeks post-product
|
Grade 3 or higher AST elevation was defined as ≥ 2.6 times the upper limit of normal
|
Through 52 weeks on product and 4 weeks post-product
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
---|---|---|
Plasma HIV RNA Level (HIV-1 Viral Load)
Временное ограничение: up to 16 weeks
|
Viral load at the time of HIV detection, HIV conversion and through 16 weeks
|
up to 16 weeks
|
CD4+ T-cell Count
Временное ограничение: Up to 16 weeks
|
CD4+ T-cell Count at the Time of HIV Seroconversion through 16 weeks
|
Up to 16 weeks
|
FTC and/or Tenofovir Resistance
Временное ограничение: up to 52 weeks
|
Genotypic resistance to FTC and/or tenofovir at the time of HIV diagnosis and 4 weeks later. If resistance was present, testing was repeated at weeks 12, 24, 36 and 52 as necessary (resistance testing will stop if no resistance is detected). participants were classified as having resistance if they had one or more visits in which resistance was detected, even if the resistance became undetectable over time. |
up to 52 weeks
|
Pregnancy Complications
Временное ограничение: up to 60 weeks
|
Reported complications during pregnancy, including spontaneous abortion, vaginal or uterine bleeding, emergency c-section and other complications
|
up to 60 weeks
|
Pill Counts and Participant Report of Adherence to Once-daily Pill Taking
Временное ограничение: Up to 52 weeks
|
Pill counts and participant report of adherence to once-daily pill taking reported as mean days study product could have been used according to pill counts
|
Up to 52 weeks
|
Participant Report of Change in Number of Sexual Partners
Временное ограничение: Up to 52 weeks
|
Difference in mean number of reported sexual partners between final study visit and enrollment visit
|
Up to 52 weeks
|
Соавторы и исследователи
Спонсор
Следователи
- Главный следователь: Lut Van Damme, MD, MS, PhD, FHI 360
- Главный следователь: Amy Corneli, PhD, MPH, FHI 360
- Директор по исследованиям: Jennifer Deese, MPH, FHI 360
Публикации и полезные ссылки
Общие публикации
- Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Malahleha M, Owino F, Manongi R, Onyango J, Temu L, Monedi MC, Mak'Oketch P, Makanda M, Reblin I, Makatu SE, Saylor L, Kiernan H, Kirkendale S, Wong C, Grant R, Kashuba A, Nanda K, Mandala J, Fransen K, Deese J, Crucitti T, Mastro TD, Taylor D; FEM-PrEP Study Group. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012 Aug 2;367(5):411-22. doi: 10.1056/NEJMoa1202614. Epub 2012 Jul 11.
- Mandala J, Nanda K, Wang M, De Baetselier I, Deese J, Lombaard J, Owino F, Malahleha M, Manongi R, Taylor D, Van Damme L. Liver and renal safety of tenofovir disoproxil fumarate in combination with emtricitabine among African women in a pre-exposure prophylaxis trial. BMC Pharmacol Toxicol. 2014 Dec 24;15:77. doi: 10.1186/2050-6511-15-77.
- Grant RM, Liegler T, Defechereux P, Kashuba AD, Taylor D, Abdel-Mohsen M, Deese J, Fransen K, De Baetselier I, Crucitti T, Bentley G, Agingu W, Ahmed K, Damme LV. Drug resistance and plasma viral RNA level after ineffective use of oral pre-exposure prophylaxis in women. AIDS. 2015 Jan 28;29(3):331-7. doi: 10.1097/QAD.0000000000000556.
- Todd CS, Deese J, Wang M, Hubacher D, Steiner MJ, Otunga S, Van Damme L; FEM-PrEP Study Group. Sino-implant (II)(R) continuation and effect of concomitant tenofovir disoproxil fumarate-emtricitabine use on plasma levonorgestrel concentrations among women in Bondo, Kenya. Contraception. 2015 Mar;91(3):248-52. doi: 10.1016/j.contraception.2014.10.008. Epub 2014 Oct 22.
Даты записи исследования
Изучение основных дат
Начало исследования
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Оценивать)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
- РНК-вирусные инфекции
- Вирусные заболевания
- Инфекции
- Инфекции, передающиеся через кровь
- Передающиеся заболевания
- Заболевания, передающиеся половым путем, вирусные
- Заболевания, передающиеся половым путем
- Лентивирусные инфекции
- Ретровирусные инфекции
- Синдромы иммунологического дефицита
- Заболевания иммунной системы
- ВИЧ-инфекции
- Молекулярные механизмы фармакологического действия
- Противоинфекционные агенты
- Противовирусные агенты
- Ингибиторы обратной транскриптазы
- Ингибиторы синтеза нуклеиновых кислот
- Ингибиторы ферментов
- Агенты против ВИЧ
- Антиретровирусные агенты
- Тенофовир
- Эмтрицитабин
- Комбинация эмтрицитабина и тенофовира дизопроксила фумарата
Другие идентификационные номера исследования
- 10015 (Другой идентификатор: Fred Hutch/University of Washington Cancer Consortium)
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Truvada
-
HIV Prevention Trials NetworkGilead SciencesАктивный, не рекрутирующийПрофилактика ВИЧСоединенные Штаты, Бразилия
-
University of California, Los AngelesGilead Sciences; University of Cape Town; Desmond Tutu HIV FoundationЗавершенный
-
ANRS, Emerging Infectious DiseasesРекрутинг
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... и другие соавторыЗавершенный
-
Johns Hopkins UniversityОтозванБеременность | ВИЧ-1-инфекция
-
University of Colorado, DenverЗавершенныйЗдоровые волонтеры | Фармакокинетика
-
Merck Sharp & Dohme LLCЗавершенный
-
CHU de Quebec-Universite LavalJohns Hopkins University; Gilead Sciences; Imperial College London; Bill and Melinda... и другие соавторыЗавершенныйСоблюдение режима приема лекарствБенин
-
National Institute of Allergy and Infectious Diseases...ЗавершенныйВИЧ-инфекцииМалави, Южная Африка, Танзания, Зимбабве, Индия, Уганда, Замбия
-
University of North Carolina, Chapel HillEunice Kennedy Shriver National Institute of Child Health and Human Development... и другие соавторыЗавершенныйВИЧ-инфекцияСоединенные Штаты